

[illegible]

<400> 1							
ggcaccocggc	ctgtgccagc	ttgcagagct	caccagggtgc	agaccocctgc	ggccaggggcg	60	
aggacggatc	tgagcagctg	ggcagcaggt	gccaccgcct	gtgggaccca	gagggccttga	120	
ggacatctgc	aatgctccag	aagcccaaga	gcgtgaagct	gcggggccctg	cgcagcccga	180	
ggaagttcgg	cgtggctggc	cggagctgcc	aggaggtgct	gcgcgaagggc	tgtctccgct	240	
tccagctccc	tgagcgcggc	tcccggctgt	gcctgtacga	ggatggcacg	gagctgacgg	300	
aagattactt	ccccagtggt	cccgacaacg	ccgagctggt	gctgctcacc	ttggggccagg	360	
cctggcaggg	ctatgtgagc	gacatcaggc	gcttcctcag	tgcatttcac	gagccacagg	420	
tggggctcat	ccaggccggc	cagcagctgc	tgtgtgatga	gcaggcccca	cagaggcaga	480	
ggctgctggc	tgacctcctg	cacaacgtca	gccagaacat	cgcggccgag	acccgggctg	540	
aggaccocgc	gtggtttgaa	ggcttggagt	cccgatttca	gagcaagtct	ggctatctga	600	
gatacagctg	tgagagccgg	atccggagtt	acctgaggga	ggtgagctcc	taccctcca	660	
cagtgggtgc	ggaggctcag	gaggaattcc	tgcgggtcct	cggctccatg	tgccagaggc	720	
tccggtccat	gcagtacaat	ggcagctact	tcgacagagg	agccaagggc	ggcagccgcc	780	
tctgcacacc	ggaaggctgg	ttctcctgcc	agggtccttt	tgacatggac	agctgcttat	840	
caagacactc	catcaacccc	tacagtaaca	gggagagcag	gatcctcttc	agcacctgga	900	
acctggatca	cataatagaa	aagaaaacgca	ccatcattcc	tacactggtg	gaagcaatta	960	
aggaacaaga	tggaagagaa	gtggactggg	agtattttta	tggcctgctt	tttacctcag	1020	
agaacctaaa	actagtgcac	attgtctgcc	ataagaaaac	caccacaag	ctcaactgtg	1080	
acccgagcag	aatctacaaa	cccagacaa	ggttgaagcg	gaagcagcct	gtgcggaaac	1140	
gccagtgaca	cgtacacacc	acgtcctggt	ctttgttttg	ggcctgacgt	gggcattcatt	1200	
ttaacaggtg	ccttttttgt	ttttttgttt	ttcgtttttt	tggctactcc	agtagctcct	1260	
ggaaaaaacc	ttaaaaaatg	tttcctccaa	atctgatttc	attacatttc	tgaattgttg	1320	
qgtttttttt	tgtttgtttg	ttttgttttg	tagatggagt	ttcacttttg	ttgccaggcg	1380	

[illegible]

<211> 338

<212> PRT

<213> Homo sapiens

<400> 2

Arg Lys Phe Gly Val Ala Gly Arg Ser Cys Gln Glu Val Leu Arg Lys
20 25 30

Gly Cys Leu Arg Phe Gln Leu Pro Glu Arg Gly Ser Arg Leu Cys Leu
35 40 45

Tyr Glu Asp Gly Thr Glu Leu Thr Glu Asp Tyr Phe Pro Ser Val Pro
50 55 60

Asp Asn Ala Glu Leu Val Leu Leu Thr Leu Gly Gln Ala Trp Gln Gly
65 70 75 80

Tyr Val Ser Asp Ile Arg Arg Phe Leu Ser Ala Phe His Glu Pro Gln
 85 90 95
 Val Gly Leu Ile Gln Ala Ala Gln Gln Leu Leu Cys Asp Glu Gln Ala
 100 105 110
 Pro Gln Arg Gln Arg Leu Leu Ala Asp Leu Leu His Asn Val Ser Gln
 115 120 125
 Asn Ile Ala Ala Glu Thr Arg Ala Glu Asp Pro Pro Trp Phe Glu Gly
 130 135 140
 Leu Glu Ser Arg Phe Gln Ser Lys Ser Gly Tyr Leu Arg Tyr Ser Cys
 145 150 155 160
 Glu Ser Arg Ile Arg Ser Tyr Leu Arg Glu Val Ser Ser Tyr Pro Ser
 165 170 175
 Thr Val Gly Ala Glu Ala Gln Glu Glu Phe Leu Arg Val Leu Gly Ser
 180 185 190
 Met Cys Gln Arg Leu Arg Ser Met Gln Tyr Asn Gly Ser Tyr Phe Asp
 195 200 205
 Arg Gly Ala Lys Gly Gly Ser Arg Leu Cys Thr Pro Glu Gly Trp Phe
 210 215 220
 Ser Cys Gln Gly Pro Phe Asp Met Asp Ser Cys Leu Ser Arg His Ser
 225 230 235 240
 Ile Asn Pro Tyr Ser Asn Arg Glu Ser Arg Ile Leu Phe Ser Thr Trp
 245 250 255
 Asn Leu Asp His Ile Ile Glu Lys Lys Arg Thr Ile Ile Pro Thr Leu
 260 265 270
 Val Glu Ala Ile Lys Glu Gln Asp Gly Arg Glu Val Asp Trp Glu Tyr
 275 280 285
 Phe Tyr Gly Leu Leu Phe Thr Ser Glu Asn Leu Lys Leu Val His Ile
 290 295 300
 Val Cys His Lys Lys Thr Thr His Lys Leu Asn Cys Asp Pro Ser Arg
 305 310 315 320
 Ile Tyr Lys Pro Gln Thr Arg Leu Lys Arg Lys Gln Pro Val Arg Lys
 325 330 335

00227-154460

[illegible]

```
<220>
<221> CDS
<222> (113)..(1105)
```

[illegible]

65						70						75					80
Ser	Asn	Thr	Lys	Phe	Val	Ala	Leu	Ala	Ser	Asn	Glu	Lys	Trp	Ala	Tyr		
				85					90					95			
Asn	Asn	Ser	Asp	Gly	Gly	Thr	Ala	Trp	Ile	Ser	Gln	Glu	Ser	Phe	Asp		
			100					105					110				
Val	Asp	Glu	Thr	Asp	Ser	Gly	Ala	Gly	Leu	Lys	Trp	Lys	Asn	Val	Ala		
		115					120					125					
Arg	Glu	Leu	Lys	Glu	Asp	Leu	Ser	Ser	Ile	Ile	Leu	Leu	Ser	Glu	Glu		
	130					135					140						
Asp	Leu	Gln	Met	Leu	Val	Asp	Ala	Pro	Cys	Ser	Asp	Leu	Ala	Gln	Glu		
145					150				155						160		
Leu	Arg	Gln	Ser	Cys	Ala	Thr	Val	Gln	Arg	Leu	Gln	His	Thr	Leu	Gln		
				165				170						175			
Gln	Val	Leu	Asp	Gln	Arg	Glu	Glu	Val	Arg	Gln	Ser	Lys	Gln	Leu	Leu		
		180						185					190				
Gln	Leu	Tyr	Leu	Gln	Ala	Leu	Glu	Lys	Glu	Gly	Ser	Leu	Leu	Ser	Lys		
	195						200					205					
Gln	Glu	Glu	Ser	Lys	Ala	Ala	Phe	Gly	Glu	Glu	Val	Asp	Ala	Val	Asp		
	210					215					220						
Thr	Gly	Met	Ser	Arg	Glu	Thr	Ser	Ser	Asp	Val	Ala	Leu	Ala	Ser	His		
225					230				235						240		
Ile	Leu	Thr	Ala	Leu	Arg	Glu	Lys	Gln	Ala	Pro	Glu	Leu	Ser	Leu	Ser		
				245				250						255			
Ser	Gln	Asp	Leu	Glu	Leu	Val	Thr	Lys	Glu	Asp	Pro	Lys	Ala	Leu	Ala		
		260						265					270				
Val	Ala	Leu	Asn	Trp	Asp	Ile	Lys	Lys	Thr	Glu	Thr	Val	Gln	Glu	Ala		
	275						280					285					
Cys	Glu	Arg	Glu	Leu	Ala	Leu	Arg	Leu	Gln	Gln	Thr	Gln	Ser	Leu	His		
	290					295					300						
Ser	Leu	Arg	Ser	Ile	Ser	Ala	Ser	Lys	Ala	Ser	Pro	Pro	Gly	Asp	Leu		
305					310				315						320		
Gln	Asn	Pro	Lys	Arg	Ala	Arg	Gln	Asp	Pro	Thr							

```
<210> 5
<211> 26
<212> DNA
<213> Artificial Sequence
```

```
<220>  
<221> modified_base  
<222> (6)..(12)  
<223> N = Inosine
```

```
<220>
<221> modified_base
<222> (11)..(15)
<223> R = A or G
```

```
<220>  
<221> modified_base  
<222> (18)..(24)  
<223> Y = C or T
```

```
<220>  
<221> modified_base  
<222> (10)  
<223> W = A or T
```

<220>
<223> Description of Artificial Sequence: Synthetic
Primer

<400> 5
gaggtnganw rngartaytt ytaygg

26

```
<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: Synthetic
Primer

```
<400> 6
atttaggtga cactatagaa
```

20

<223> R = A or G

<220>

<221> modified_base

<222> (15)

<223> D = G, C or A

<220>

<223> Description of Artificial Sequence: Synthetic
Primer

<400> 8

gtytgnggyt trtadat

17

<210> 9

<211> 30

<212> DNA

<213> Homo sapiens

<400> 9

tcagagaacc taaaactagt gcacattgtc

30

<210> 10

<211> 30

<212> DNA

<213> Homo sapiens

<400> 10

tgccataaga aaaccaccca caagctcaac

30

<210> 11

<211> 31

<212> DNA

<213> Homo sapiens

<400> 11

atccgatatc atgctccaga agcccaagag c

31

<210> 12

<211> 58

<212> DNA

<213> Homo sapiens

<400> 12

atccctcgag tcaattgtcg tcgtcgctct tgtagtcctg gcgtttccgc acaggctg 58

<210> 13
<211> 43
<212> DNA
<213> Homo sapiens

<400> 13
cccctctaga atagaaggag atatgctcca gaagcccaag agc 43

<210> 14
<211> 52
<212> DNA
<213> Homo sapiens

<400> 14
atccctcgag tcaatgatga tgatgatgat gctggcgttt ccgcacaggc tg 52

<210> 15
<211> 40
<212> DNA
<213> Homo sapiens

<400> 15
atccctcgag gaaggagata tggaggtgac cggggacgcc 40

<210> 16
<211> 33
<212> DNA
<213> Homo sapiens

<400> 16
agaatactcg agctatgtgg gatacctgtct ggc 33

<210> 17
<211> 30
<212> DNA
<213> Homo sapiens

<400> 17
gacatctcat atgctccaga agcccaagag 30

002237.F34260

<210> 18
<211> 30
<212> DNA
<213> Homo sapiens

<400> 18
gtcaggcctc gagcaaagac caggacgtgg

30

<210> 19
<211> 9
<212> PRT
<213> Mus musculus

<400> 19
Glu Val Asp Trp Glu Tyr Phe Tyr Gly
1 5

<210> 20
<211> 9
<212> PRT
<213> Mus musculus

<400> 20
Glu Tyr Phe Tyr Gly Leu Leu Phe Thr
1 5

<210> 21
<211> 6
<212> PRT
<213> Mus musculus

<400> 21
Ile Tyr Lys Pro Gln Thr
1 5

APPENDIX A:
Claims Pending after Preliminary Amendment

91. An isolated DNA fragmentation factor complex for regulating chromatin stability, said complex comprising a DFF40 polypeptide and a DFF45 polypeptide.
94. The complex of claim 91, wherein the DFF40 subunit comprises 20 contiguous amino acids of SEQ ID NO:2.
95. The complex of claim 94, wherein the DFF40 subunit comprises 30 contiguous amino acids of SEQ ID NO:2.
96. The complex of claim 95, wherein the DFF40 subunit comprises 50 contiguous amino acids of SEQ ID NO:2.
97. The complex of claim 96, wherein the DFF40 subunit comprises 100 contiguous amino acids of SEQ ID NO:2.
98. The complex of claim 97, wherein the DFF40 subunit comprises SEQ ID NO:2.
99. The complex of claim 91, wherein the DFF45 subunit comprises 20 contiguous amino acids of SEQ ID NO:4.
100. The complex of claim 99, wherein the DFF45 subunit comprises 30 contiguous amino acids of SEQ ID NO:4.
101. The complex of claim 100, wherein the DFF45 subunit comprises 50 contiguous amino acids of SEQ ID NO:4.
102. The complex of claim 101, wherein the DFF45 subunit comprises 100 contiguous amino acids of SEQ ID NO:4.

103. The complex of claim 102, wherein said DFF45 subunit comprises SEQ ID NO:4.
104. An isolated polypeptide encoding a human DFF40 DNA fragmentation factor.
105. The polypeptide of claim 104, wherein the DNA fragmentation factor comprises 20 contiguous amino acids of SEQ ID NO:2 [check sequence against CAD].
106. The polypeptide of claim 104, wherein the DNA fragmentation factor comprises 30 contiguous amino acids of SEQ ID NO:2.
107. The polypeptide of claim 104, wherein the DNA fragmentation factor comprises 50 contiguous amino acids of SEQ ID NO:2.
108. The polypeptide of claim 104, wherein the DNA fragmentation factor comprises 100 contiguous amino acids of SEQ ID NO:2.
109. The polypeptide of claim 104, wherein the DNA fragmentation factor comprises SEQ ID NO:2.
110. The polypeptide of claim 104, further comprising a second polypeptide.
111. The polypeptide of claim 110, wherein the second polypeptide is an antibody.
112. The polypeptide of claim 110, wherein the second polypeptide comprises a DFF45 fragmentation factor.
113. An isolated peptide having between about 10 and about 100 contiguous amino acids of a human DFF40 DNA fragmentation factor.

114. The peptide of claim 113, wherein the peptide comprises 20 contiguous amino acids of SEQ ID NO:2.

115. The peptide of claim 114, wherein the peptide comprises 30 contiguous amino acids of SEQ ID NO:2.

116. The peptide of claim 113, wherein the peptide is conjugated to a carrier molecule.

117. The peptide of claim 116, wherein the carrier molecule is selected from the group consisting of KLH and BSA.

[illegible]